Surrozen, Inc.
A clinical-stage biotech that turns the body's own repair signals into medicines, Surrozen builds antibody drugs that mimic Wnt proteins — the natural molecules that tell tissue to regenerate. Founded in 2015 by Stanford and other scientists, its lead work targets sight-threatening eye diseases like wet age-related macular degeneration. The name blends "surrogate" and "zen": the engineered antibodies act as stand-ins for the body's repair messengers, long considered impossible to turn into drugs.
Warrant expiring August 1, 2031
Bought 170.9K
Granted 6.0K · Sold 1.6K
Granted 7.3K · Sold 2.0K
Granted 14.1K · Sold 4.5K
Granted 607
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| TCG Crossover Fund II, L.P. +3 co-filers10% owner · 10 transactions | +13.1% | 1.47M | — | 170.9K | — |
| Li YangExec. Vice President, Research · 4 transactions | +16% | 20.3K | 6.0K | — | 1.6K |
| Williams Charles OChief Operating Officer · 3 transactions | +40.5% | 18.2K | 7.3K | — | 2.0K |
| Parker Craig CChief Executive Officer, Director · 3 transactions | +111.9% | 18.2K | 14.1K | — | 4.5K |
| Maleki Andrew PedrumChief Financial Officer · 1 transaction | — | 607 | 607 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +162.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.